As of 2026-04-05, the EV/EBITDA ratio of Fate Therapeutics Inc (FATE) is -0.71. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. FATE's latest enterprise value is 95.21 mil USD. FATE's TTM EBITDA according to its financial statements is -134.71 mil USD. Dividing these 2 quantities gives us the above FATE EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 9.7x - 14.3x | 12.0x |
| Forward P/E multiples | 15.0x - 17.8x | 16.5x |
| Fair Price | (16.93) - (16.12) | (16.08) |
| Upside | -1488.0% - -1421.5% | -1418.1% |
| Date | EV/EBITDA |
| 2026-04-02 | -0.71 |
| 2026-04-01 | -0.72 |
| 2026-03-31 | -0.69 |
| 2026-03-30 | -0.63 |
| 2026-03-27 | -0.66 |
| 2026-03-26 | -0.72 |
| 2026-03-25 | -0.71 |
| 2026-03-24 | -0.63 |
| 2026-03-23 | -0.65 |
| 2026-03-20 | -0.60 |
| 2026-03-19 | -0.59 |
| 2026-03-18 | -0.57 |
| 2026-03-17 | -0.63 |
| 2026-03-16 | -0.65 |
| 2026-03-13 | -0.66 |
| 2026-03-12 | -0.66 |
| 2026-03-11 | -0.72 |
| 2026-03-10 | -0.77 |
| 2026-03-09 | -0.80 |
| 2026-03-06 | -0.80 |
| 2026-03-05 | -0.84 |
| 2026-03-04 | -0.91 |
| 2026-03-03 | -0.84 |
| 2026-03-02 | -0.95 |
| 2026-02-27 | -0.93 |
| 2026-02-26 | -1.00 |
| 2026-02-25 | -0.93 |
| 2026-02-24 | -1.05 |
| 2026-02-23 | -0.96 |
| 2026-02-20 | -0.91 |
| 2026-02-19 | -0.86 |
| 2026-02-18 | -0.84 |
| 2026-02-17 | -0.81 |
| 2026-02-13 | -0.73 |
| 2026-02-12 | -0.69 |
| 2026-02-11 | -0.66 |
| 2026-02-10 | -0.59 |
| 2026-02-09 | -0.62 |
| 2026-02-06 | -0.64 |
| 2026-02-05 | -0.56 |
| 2026-02-04 | -0.65 |
| 2026-02-03 | -0.65 |
| 2026-02-02 | -0.72 |
| 2026-01-30 | -0.68 |
| 2026-01-29 | -0.68 |
| 2026-01-28 | -0.70 |
| 2026-01-27 | -0.78 |
| 2026-01-26 | -0.72 |
| 2026-01-23 | -0.70 |
| 2026-01-22 | -0.73 |